Home Featured Page 249

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Microdosing LSD Makes Me a Better Mom

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Microdosing LSD Makes Me a Better Mom

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the...

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY